

*Claim 1*  
for prevention and/or treatment of atherosclerosis, comprising an active component selected from the group consisting of modified low density lipoprotein, oxidized low density lipoprotein (Ox LDL), heat shock protein 60/65 (HSP 60/65), beta<sub>2</sub>-glycoprotein-1 ( $\beta_2$ -GP-1), functional derivatives thereof and mixtures thereof, in combination with a pharmaceutically acceptable carrier for oral administration, the composition being formulated for inducing oral tolerance.

*Amended*  
*Claim 12*  
12. (Amended) An immunological tolerance-inducing composition according to claim 1, wherein said active component is lysophosphatidyl choline (LPC).

*Amended*  
*Claim 14*  
14. (Amended) A method for prevention and/or treatment of atherosclerosis in a subject, comprising administering an immunological oral tolerance-inducing composition comprising an active component selected from the group consisting of modified low density lipoprotein, oxidized low density lipoprotein (Ox LDL), heat shock protein 60/65 (HSP 60/65), beta<sub>2</sub>-glycoprotein-1 ( $\beta_2$ GP-1), functional derivatives thereof and mixtures thereof, in combination with a pharmaceutically acceptable carrier for oral administration, thereby inhibiting at least one atherosclerosis-related symptom in said subject.

25. (Amended) A method according to claim 14, wherein said active component is lysophosphatidyl choline (LPC).

#### REMARKS

Reconsideration of the above-identified application in view of the amendments above and the remarks following is respectfully requested.